PHVS jumps after positive topline HAE trial results
Pharvaris (PHVS) shares rose after the company disclosed positive topline data from a hereditary angioedema (HAE) trial. The stock gained 11% to $39.26 on Tuesday.
By Katherine HamiltonPharvaris shares rose after the company disclosed positive topline data from a trial of a treatment for the genetic disorder hereditary angioedema (HAE).The stock gained 11% to $39.26 on Tuesday. Shares are up 48% over the past year.The Swiss biopharmaceutical company said its…